Response-independent survival benefit in metastatic colorectal cancer: A comparative analysis of N9741 and AVF2107

Journal of Clinical Oncology

Volumn 26, Issue 2, 2008, Pages 183-189

  Grothey, Axel ^a   Hedrick, Eric E ^a   Mass, Robert D ^a   Sarkar, Somnath ^a   Suzuki, Sam ^a   Ramanathan, Ramesh K ^a   Hurwitz, Herbert I ^a   Goldberg, Richard M ^a   Sargent, Daniel J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLACEBO;

ARTICLE; CANCER SURVIVAL; COLORECTAL CARCINOMA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG MECHANISM; HAZARD RATIO; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; METASTASIS; METHODOLOGY; MONOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MULTICENTER STUDIES AS TOPIC; ORGANOPLATINUM COMPOUNDS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 38349189743     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.8099     Document Type: Article

References (25)

1. Grothey A, Sargent D, Goldberg RM, et al: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209-1214, 2004
2. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
3. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000
4. Giacchetti S, Perpoint B, Zidani R, et al: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136-147, 2000
5. Grothey A, Deschler B, Kroening H, et al: Phase III study of bolus 5-fluorouracil (5-FU)/ folinic acid (FA) (Mayo) vs. weekly high-dose 24h 5-FU infusion/ FA + oxaliplatin (OXA) in advanced colorectal cancer (ACRC). J Clin Oncol 21:129s, 2002 (suppl; abstr 512)
6. Kohne CH, van Cutsem E, Wils J, et al: Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 23:4856-4865, 2005
7. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 343:905-914, 2000
8. Goldberg RM, Sargent D, Morton RF, et al: N9741: FOLFOX (oxaliplatin(Oxal)/ 5-fluorouracil (5-FU)/ leucovorin (LV) or reduced dose R-IFL (CPT-11 + 5-FU/LV) in advanced colorectal cancer (CRC): Final efficacy data from an intergroup study. J Clin Oncol 23:275s, 2004 (suppl; abstr 3621)
9. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
10. Grothey A: Integrating biologics and chemotherapy in the systemic treatment of advanced colorectal cancer. Presented at Gastrointestinal Cancers Symposium, San Francisco, CA, January 26-28, 2006
11. Kim KJ, Li B, Winer J, et al: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841-844, 1993
12. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
13. Kerbel RS: Clinical trials of antiangiogenic drugs: Opportunities, problems, and assessment of initial results. J Clin Oncol 19:45S-51S, 2001
14. Korn EL, Arbuck SG, Pluda JM, et al: Clinical trial designs for cytostatic agents: Are new approaches needed? J Clin Oncol 19:265-272, 2001
15. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004
16. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, World Health Organization, Offset publication 48, 1979
17. ODAC: Colorectal Cancer Endpoints Meeting on May 4, 2004. http://www.fda.gov/ohrms/dockets/ ac/04/transcripts/4037T2.htm
18. Buyse M, Thirion P, Carlson RW, et al: Re: A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer. J Natl Cancer Inst 93:399-401, 2001
19. Campbell M, Grothey A, Sargent D, et al: Waterfall plots provide detailed information on magnitude of response to conventional chemotherapy in advanced colorectal cancer (ACRC): Lessons learned from N9741. J Clin Oncol 25:4080, 2007
20. Ratain MJ, Eisen T, Stadler WM, et al: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505-2512, 2006
21. Buyse M, Molenberghs G: Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics 54:1014-1029, 1998
22. Buyse M, Burzykowski T, Carroll K, et al: Progression-free survival (PFS) as a surrogate for overall survival (OS) in patients with advanced colorectal cancer: An analysis of 3159 patients randomized in 11 trials. J Clin Oncol 23s:3513, 2005 (suppl; abstr XX)
23. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134, 2007
24. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966, 2007
25. Cassidy J, Clarke S, Diaz Rubio E, et al: First efficacy and safety results from XELOX-1/NO16966, a randomised 2x2 factorial phase III trial of XELOX vs. FOLFOX4 + bevacizumab or placebo in first-line metastatic colorectal cancer (MCRC). Ann Oncol 17:LBA3, 2006 (suppl 9)